Clinical Trial: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184645) titled 'A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis' on Sept. 18.

Brief Summary: To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis (AD)

Intervention: DRUG: OPA-15406

0.3% foam or 1% foam, topical, twice daily, for 8 weeks

DRUG: Vehicle

vehicle, topical, twice daily, for 8 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Otsuka Pharmaceutical Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....